Red Light Holland announces successfully importing its psilocybin microdose packs from the Netherlands into Canada.
Numinus Wellness announces Health Canada approval of its application to use psilocybin-assisted therapy for treatment-resistant depression (TRD).
Field Trip launches a telehealth version of its ketamine-assisted therapy, via a partnership with Nue Life Health.
Mindset Pharma announces initial planning of its Phase 1 clinical trials for its first family of novel molecules.
MindMed announces it will host a webinar on substance abuse disorders and withdrawal management that includes prominent experts in this field.
Revitalist Lifestyle and Wellness reports strong month-over-month and year-over-year revenue gains from its ketamine clinic operations.
Enveric Bioscience announces it is spinning off its cannabinoid R&D pipeline into a stand-alone entity.
Optimi Health announces the completion of its previously announced lab expansion for its Princeton, British Columbia facility.
A plethora of drug R&D opportunities. A multitude of badly under-served healthcare treatment markets. A medical "miracle"; an investment pot of gold.